Rankings
▼
Calendar
LAB Q4 2024 Earnings — Standard BioTools Inc. Revenue & Financial Results | Market Cap Arena
LAB
Standard BioTools Inc.
$388M
Q4 2024 Earnings
Healthcare
Medical - Devices
Income Statement
Revenue
$47M
+65.7% YoY
Gross Profit
$22M
46.9% margin
Operating Income
-$33M
-70.2% margin
Net Income
-$34M
-72.9% margin
EPS (Diluted)
$-0.09
QoQ Revenue Growth
+3.9%
Cash Flow
Operating Cash Flow
-$14M
Free Cash Flow
-$17M
Stock-Based Comp.
$7M
Balance Sheet
Total Assets
$612M
Total Liabilities
$141M
Stockholders' Equity
$472M
Cash & Equivalents
$167M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$47M
$28M
+65.7%
Gross Profit
$22M
$13M
+64.0%
Operating Income
-$33M
-$21M
-53.5%
Net Income
-$34M
-$20M
-72.3%
Revenue Segments
Product And Service
$81M
37%
Product
$45M
21%
Service
$36M
16%
Consumables
$36M
16%
Instruments
$18M
8%
Collaboration and Other Revenue
$3M
1%
Geographic Segments
Americas
$45M
54%
EMEA
$24M
28%
Asia Pacific
$15M
18%
← FY 2024
All Quarters
Q1 2025 →